Follow us on:

Poolbeg Pharma in-licencing exciting programmes ready for big pharma (Interview)

Poolbeg Pharma plc (LON:POLB) CEO Jeremy Skillington joins DirectorsTalk Interviews to discuss the in-licencing of a novel, first-in-class RNA-based immunotherapy for respiratory virus infections.

Jeremy tells us more about this new deal, explains the terms, what being at a late pre-clinical stage means and explains the ultimate plan for this asset.

Poolbeg Pharma (LON: POLB) is a clinical stage infectious disease pharmaceutical company, with a clinical model which enables them to develop multiple products faster and more cost effectively than a traditional biotech model.

You might also enjoy reading Poolbeg Pharma Powering Ahead with Groundbreaking Treatments and Strategic Growth, Cavendish Comments

Find more news, interviews, share price & company profile here for:Poolbeg Pharma plc

Share this interview

Other Interviews

Poolbeg Pharma A Strategic Vision, Pioneering the Future of Innovative Medicine January 26, 2024
Poolbeg Pharma advancing products, platforms and opportunities (VIDEO) September 7, 2022
Poolbeg Pharma to develop oral vaccine delivery platform (Interview) December 17, 2021
Poolbeg Pharma partner with Eurofins Genomics for AI data analysis (Interview) October 11, 2021

More News

Poolbeg Pharma awarded POLB 001 patent in United States November 20, 2024
Poolbeg Pharma to present POLB 001 data at 66th ASH Annual Meeting and Exposition November 6, 2024
Poolbeg Pharma patent portfolio significantly strengthened & expanded September 18, 2024
FTSE AIM top share risers: LON:TIME, CER, QED, HERC, POLB, SAE August 22, 2024
Poolbeg Pharma relocates to new London headquarters at 40 Bank Street July 2, 2024
Poolbeg Pharma publishes Annual Report and AGM Notice May 9, 2024
Poolbeg Pharma granted significant POLB 001 patent in United States May 1, 2024
Poolbeg Pharma enters Exclusive Option Agreement for novel Behçet’s Disease treatment April 30, 2024
Poolbeg Pharma’s POLB 001 has great potential to generate significant value for shareholders April 30, 2024
Poolbeg Pharma Receives Notice of Allowance for Immunomodulator II Patent March 20, 2024

Search

Useful links

Disclaimer

You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular stock, share, security, portfolio of securities, transaction, investment strategy, or other matter. We openly disclose that we and our contributors may have interests in investments and/or providers of services referred to within the website and that we receive remuneration from certain of the companies referred to on this website.

© 2024 – DirectorsTalk Interviews. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.